Nasdaq · Healthcare
RAPID MICRO BIOSYSTEMS, INC. (RPID)
As-reported financials and recent SEC filings for RAPID MICRO BIOSYSTEMS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$33.6M
Net income
$-47.1M
Net margin
-140.3%
Diluted EPS
$-1.05
ROE
-141.9%
P/E (TTM)
—
Market cap
—
Debt / equity
0.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $33.6M | $28.1M | $22.5M | $17.1M | $23.2M |
| Gross profit | — | — | — | — | — |
| Operating income | $-47.4M | $-49.9M | $-56.6M | $-63.2M | $-47.2M |
| Net income | $-47.1M | $-46.9M | $-52.5M | $-60.8M | $-73.5M |
| Diluted EPS | $-1.05 | $-1.08 | $-1.22 | $-1.43 | $-1.97 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-07-01
View on EDGAR →1442026-06-22
View on EDGAR →1442026-06-10
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →Largest Healthcare peers
Go deeper on RPID
Search RAPID MICRO BIOSYSTEMS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.